Fig. 4.

Mesenchymal deletion of Gli2 ameliorates pancreatic defects in Sufu mesKOs. a–c Representative E17.5 control a, Bapx1^Cre/+;Sufu^f/f mutant b, and Bapx1^Cre/+;Gli2^f/f;Sufu^f/f rescue gut c. St- Stomach, Int- Intestine, Panc- Pancreas. d–f Immunostaining for INS and AMY in control E17.5 d, Bapx1^Cre/+;Sufu^f/f mutant e, and Bapx1^Cre/+;Gli2^f/f;Sufu^f/f rescue pancreata f. g–i Co-staining for DES and SMA in E17.5 control g, Bapx1^Cre/+;Sufu^f/f mutant h, and Bapx1^Cre/+;Gli2^f/f;Sufu^f/f pancreatic mesenchyme i. BV- Blood vessel. j Comparison of the ratios in E17.5 pancreatic volume between Bapx1^Cre/+;Sufu^f/f mutants and their controls vs. Bapx1^Cre/+;Gli2^f/f;Sufu^f/f rescues and their controls (n = 3 samples of each genotype). k Comparison of INS⁺ to GCG⁺ cell ratios in Bapx1^Cre/+;Sufu^f/f and Bapx1^Cre/+;Gli2^f/f;Sufu^f/f pancreata, normalized to controls (n = 3 control and rescue samples, n = 4 mutant samples). Data are means ± SEM. n.s. denotes not significant, * denotes p < 0.05 by Student’s un-paired, two tailed t-test. Scale bars: Whole mount- 1 mm, Immunofluorescence- 100 µm